Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ADMEcell signs agreement with Advancell
According to ADMEcell, the CacoReady system is a new tool designed to optimize the time and costs of evaluating the intestinal absorption of compounds. The kit has been
According to ADMEcell, the CacoReady system is a new tool designed to optimize the time and costs of evaluating the intestinal absorption of compounds. The kit has been
The European Commission consequently follows the positive opinion of the European Medicine Agency’s Orphan Medicinal Products Committee. The FDA granted StemEx orphan drug designation in March 2005 for
In the BST-CarGel study, VirtualScopics is providing blinded data analysis of quantitative magnetic resonance imaging which will allow BioSyntech to demonstrate BST-CarGel’s potential for affecting the quantity and
This designation provides Antigenics with, among other benefits, 10 years of potential market exclusivity if the product is approved for marketing in the EU. This is the second
The company has initiated a search for a successor that will consider internal and external candidates. Dr Pickett will continue to head R&D until his successor is appointed.
Matrix’s version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates. Lopinavir/ritonavir tablets are the generic version of Abbott Laboratories’s
According to the company, this once-daily oral medication, available in 40mg and 80mg tablets, is the first new treatment option for hyperuricemia in patients with gout in more
Mr Marver currently serves as the company’s COO and succeeds the company’s current CEO, John Hinson, who is leaving the company for personal reasons, effective March 30, 2009.
Currently, The Female Health Company (FHC) is manufacturing its second-generation product, FC2, on four production lines in Malaysia. The company, in conjunction with its Indian partner, HLL Lifecare,
The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque